Chemomab Therapeutics (CMMB) announced that David Weiner, MD, has been named Interim Chief Medical Officer, CMO, and Jack Lawler, Senior Vice President of Global Medical Operations at Chemomab, has been named Chief Development Officer, CDO.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMMB:
- Promising Phase 3 Prospects and Strategic Study Design Justify Buy Rating for Chemomab Therapeutics
- Chemomab’s Nebokitug Shows Promising Phase 2 Results for PSC
- Chemomab Therapeutics reports results in nebokitug Phase 2 PSC OLE trial
- Chemomab Therapeutics Updates ADS Offering Under Sales Agreement
- Chemomab Therapeutics Reports 2024 Financial Results and Progress